BiotechTube

CREXONT ER

ApprovedRecruiting
1 views this week 0 watching⚡ Active
Interest: 47/100
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Parkinson Disease

Conditions

Parkinson Disease

Trial Timeline

Feb 12, 2025 → Aug 6, 2026

NCT ID
NCT06765668

About CREXONT ER

CREXONT ER is a approved stage product being developed by Amneal Pharmaceuticals for Parkinson Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06765668. Target conditions include Parkinson Disease.

What happened to similar drugs?

20 of 20 similar drugs in Parkinson Disease were approved

Approved (20) Terminated (3) Active (0)
✅Mirabegron + PlaceboAstellas PharmaApproved
✅Lemborexant + placeboEisaiApproved
✅Safinamide MesilateEisaiApproved
✅Istradefylline PillKyowa KirinApproved
✅Levodopa-carbidopa intestinal gel (LCIG)AbbVieApproved
✅Carbidopa/levodopa/entacaponeNovartisApproved
✅Carbidopa/levodopa/entacapone + Immediate release carbidopa/levodopaNovartisApproved

Hype Score Breakdown

Clinical
20
Activity
15
Company
12
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT07138560ApprovedRecruiting
NCT06765668ApprovedRecruiting

Competing Products

20 competing products in Parkinson Disease

See all competitors
ProductCompanyStageHype Score
exidavnemab + Placebo ComparatorBioArctic ABPhase 2
36
UB-312 + PlaceboVaxxinityPhase 1
19
NAV5001 + DaTscanNavidea BiopharmaceuticalsPhase 3
22
LY4006896 + PlaceboEli LillyPhase 1
36
ATH-1017 + PlaceboLeonaBioPhase 2
17
piclozotan + 0.9% sodium chloride (normal saline)Daiichi SankyoPhase 2
35
Mirabegron + PlaceboAstellas PharmaApproved
43
E2007EisaiPhase 3
32
ARICEPTEisaiPhase 3
40
PerampanelEisaiPhase 3
32
GPI 1485EisaiPhase 2
35
E2007EisaiPhase 3
40
Prior Donepezil 5mg + Prior Donzepezil 10mg + Prior PlaceboEisaiPhase 3
40
Equfina 50 mgEisaiPre-clinical
26
EqufinaEisaiPre-clinical
26
perampanel + placeboEisaiPhase 2
27
Lemborexant + placeboEisaiApproved
50
Placebo + E2007 + E2007EisaiPhase 3
32
Safinamide MesilateEisaiApproved
43
E2007 + E2007 + E2007EisaiPhase 2
35